Skip to main content

Yutiq FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 29, 2018.

FDA Approved: Yes (First approved October 12, 2018)
Brand name: Yutiq
Generic name: fluocinolone acetonide
Dosage form: Intravitreal Implant
Company: EyePoint Pharmaceuticals, Inc.
Treatment for: Non-Infectious Posterior Segment Uveitis

Yutiq (fluocinolone acetonide) is a corticosteroid intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Steroid-related Effects
Patients are advised that a cataract may occur after treatment with Yutiq. If this occurs, their vision will decrease, and they will need an operation to remove the cataract.
Patients are advised that they may develop increased intraocular pressure with Yutiq treatment, and the increased IOP may need to be managed with eye drops or surgery.

Intravitreal Injection-related Effects
Patients are advised that in the days following intravitreal injection of Yutiq, they are at risk for potential complications including, but not limited to, the development of endophthalmitis or changes in intraocular pressure.

When to Seek Physician Advice
Patients are advised that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.

Driving and Using Machines
Patients are advised that they may experience temporary visual blurring after receiving an intravitreal injection. Patients should not drive or use machines until this has been resolved.

Adverse Reactions
In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Development timeline for Yutiq

Oct 15, 2018Approval FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.